First Manhattan CO Repligen Corp Transaction History

First Manhattan CO

$31.9 Billion
Q3 2024

A detailed history of First Manhattan CO transactions in Repligen Corp stock. As of the latest transaction made, First Manhattan CO holds 6,550 shares of RGEN stock, worth $946,213. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,550

Previous 6,551 0.02%

Holding current value

$946,213

Previous $825,000 18.06%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$119.79 - $167.35 $119 - $167	-1 Reduced 0.02%	6,550 $974,000
Q2 2024 Aug 13, 2024	SELL	$120.0 - $182.95 $9,480 - $14,453	-79 Reduced 1.19%	6,551 $825,000
Q4 2023 Feb 13, 2024	SELL	$114.17 - $185.35 $117,480 - $190,725	-1,029 Reduced 13.44%	6,630 $1.19 Million
Q3 2023 Nov 14, 2023	BUY	$138.78 - $176.51 $69,528 - $88,431	501 Added 7.0%	7,659 $1.22 Million
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $172,652 - $234,455	1,063 Added 17.44%	7,158 $1.21 Million
Q3 2022 Nov 14, 2022	SELL	$160.42 - $256.21 $641,680 - $1.02 Million	-4,000 Reduced 39.62%	6,095 $1.14 Million
Q1 2022 May 16, 2022	BUY	$161.19 - $257.96 $93,490 - $149,616	580 Added 6.1%	10,095 $1.9 Million
Q1 2021 May 14, 2021	BUY	$180.37 - $226.26 $104,614 - $131,230	580 Added 6.49%	9,515 $1.85 Million
Q1 2020 May 06, 2020	SELL	$84.96 - $109.14 $84,960 - $109,140	-1,000 Reduced 10.07%	8,935 $862,000
Q3 2019 Nov 13, 2019	SELL	$76.65 - $95.51 $43,307 - $53,963	-565 Reduced 5.38%	9,935 $761,000
Q4 2017 Jan 22, 2018	BUY	$32.53 - $38.92 $48,795 - $58,380	1,500 Added 16.67%	10,500 $380,000
Q3 2017 Oct 25, 2017	BUY	$36.98 - $46.06 $332,820 - $414,540	9,000	9,000 $344,000

Others Institutions Holding RGEN

# of Institutions

488

Shares Held

54.2M

Call Options Held

341K

Put Options Held

235K

View Full List

About REPLIGEN CORP

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.02B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

More about RGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.

Account

First Manhattan CO Repligen Corp Transaction History